Maintenance Treatment With Inhaled Ampicillin in Patients With Cystic Fibrosis and Lung Infection Due to Methicillin-Sensitive Staphylococcus aureus;Tratamiento de mantenimiento con ampicilina inhalada en pacientes con fibrosis quística e infección pulmonar por Staphylococcus aureus sensible a meticilina

Archivos de Bronconeumologia

Volumn 48, Issue 10, 2012, Pages 384-

  Máiz, Luis ^a   Del Campo, Rosa ^a   Castro, María ^b   Gutiérrez, Dayra ^a   Girón, Rosa ^c   Cantón Moreno, Rafael ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; GOBEMICIN;

CYSTIC FIBROSIS; HUMAN; LETTER; LUNG INFECTION; MAINTENANCE THERAPY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; BACTERIUM ISOLATION; DISEASE EXACERBATION; DRUG SYNTHESIS; DRUG USE; GENETIC VARIABILITY; HAEMOPHILUS PARAINFLUENZAE; HOSPITALIZATION; LUNG FUNCTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NEBULIZATION; NONHUMAN; RESPIRATORY TRACT INFECTION; SPUTUM; TASTE ACUITY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AMPICILLIN; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYSTIC FIBROSIS; DISEASE SUSCEPTIBILITY; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS PARAINFLUENZAE; HOSPITALIZATION; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NEBULIZERS AND VAPORIZERS; PNEUMONIA, BACTERIAL; PNEUMONIA, STAPHYLOCOCCAL; RETROSPECTIVE STUDIES; SUPERINFECTION; YOUNG ADULT;

EID: 84874766093     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2012.04.002     Document Type: Letter

References (6)

1. Besier S., Smaczny C., Von Mallinckrodt C., Krahl A., Ackermann H., Brade V., et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol 2007, 45:168-172.
2. Sagel S.D., Gibson R.L., Emerson J., McNamara S., Burns J.L., Wagener J.S., et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2008, 154:183-188. for the Inhaled Tobramycin in Young Children Study Group and the Cystic Fibrosis Foundation Therapeutics Development Network.
3. Solis A., Brown D., Hughes J., Van Saene H.K., Heaf D.P. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 2003, 36:189-195.
4. Máiz L., Lamas A., Fernández-Olmos A., Suárez L., Cantón R. Unorthodox long-term aerosolized ampicillin use for methicillin-susceptible Staphylococcus aureus lung infection in a cystic fibrosis patient. Pediatr Pulmonol 2009, 44:512-515.
5. Máiz L., Canton R., Mir N., Baquero F., Escobar H. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol 1998, 26:287-289.
6. Geller D.E., Pitlick W.H., Nardella P., Tracewell W.G., Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122:219-226.